SCHEMBL7183615

SCHEMBL7183615

O=C(c1c(Cl)cccc1Cl)[PH](=O)CCCCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 2/20 0.48
SCN2A Q99250 2/20 0.48
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ACHE P22303 1/20 0.42
SGMS1 Q86VZ5 1/20 0.42
SGMS2 Q8NHU3 1/20 0.42
BID P55957 1/20 0.41
BCL2L1 Q07817 1/20 0.41
MCL1 Q07820 1/20 0.41
BAK1 Q16611 1/20 0.41
HDAC1 Q13547 4/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC3 O15379 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA1A P35348 1/20 0.41
HDAC4 P56524 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183532 0.99 SCN5A (0.47) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7188235 0.99 SCN5A (0.47) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7190488 0.99 SCN5A (0.47) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7180510 0.99 SCN5A (0.47) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7175990 0.99 SCN5A (0.47) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7189390 0.95 SCN5A (0.46) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7187054 0.91 SCN5A (0.44) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7190243 0.90 SCN5A (0.43) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7180635 0.90 SCN5A (0.43) SCN5ASCN2APOLBMAPTRXFP1
SCHEMBL7189459 0.90 SCN5A (0.43) SCN5ASCN2APOLBMAPTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SCN5A 1196/4885SCN2A 1484/4885POLB 2322/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SCN5A 2114/4885SCN2A 2089/4885POLB 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.